Table 3.

Cost-impact analysis using modeling on therapy with sofosbuvir in combination of simeprevir, daclatasvir or ledipasvir.

Observed time to HCV RNA <15 IU/ml [days]	n (%)	Predicted number of patients and treatment duration to reach virus cure* n [weeks]	Estimated treatment cost saving (in France) to reach virus cure* compared to standard 12 weeks of therapy [x1000€]	Estimated treatment cost saving to reach virus cure* compared to standard 12 weeks of therapy in 100 subjects
2	3(5%)	3[N/A]		1%
14	25(43%)	22 [6]+ 1[10]+1[12]+1[N/A]	650	45%
28	23(40%)	1[6]+16 [8]+6[10]	397	30%
42	7(12%)	4 [12] + 3 [13]	44**	11%
Total		23[6]+16[8]+7[10]+9[12]+3[13]	1091	20%

^*Virus cure is defined as <1 virus copy in the entire extracellular body fluid;

^**additional 3 weeks of therapy (extra cost of 14,542€) but assuming that additional week would have achieved SVR in the subject who relapsed, i.e., saving of average cost (58,167€) of DAA therapy in France; N/A, not available due to insufficient viral load measurements.